Phosphagenics Initiates U.S. Clinical Trials For Its Topical Retinoic Acid

Phosphagenics Limited (”Phosphagenics”) (ASX: POH; AIM: PSG; OTCQX: PPGNY) announced the initiation of a human clinical trial for its lead dermatological product, retinoic acid, a form of vitamin A. This trial represents the Company’s first clinical trial to take place in the U.S. and denotes the commencement of the Company’s planned expansion into targeted, non-systemic delivery of drugs.

More: continued here

Filed under: Clinical Trials on February 26th, 2008